OMERS ADMINISTRATION Corp Invests $410,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

OMERS ADMINISTRATION Corp bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 7,400 shares of the company's stock, valued at approximately $410,000.

Several other hedge funds have also recently made changes to their positions in TARS. Lord Abbett & CO. LLC raised its position in shares of Tarsus Pharmaceuticals by 115.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock worth $70,873,000 after acquiring an additional 685,111 shares in the last quarter. Millennium Management LLC grew its stake in shares of Tarsus Pharmaceuticals by 189.4% in the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company's stock valued at $35,659,000 after buying an additional 421,495 shares during the period. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Tarsus Pharmaceuticals by 5,636.3% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock valued at $22,383,000 after buying an additional 397,190 shares during the period. Jennison Associates LLC boosted its stake in Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after purchasing an additional 321,552 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Tarsus Pharmaceuticals by 36.7% during the 4th quarter. Invesco Ltd. now owns 932,115 shares of the company's stock valued at $51,611,000 after purchasing an additional 250,018 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TARS. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Jefferies Financial Group lifted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Barclays cut their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $66.33.

Tarsus Pharmaceuticals Stock Performance

TARS stock traded up $0.01 during midday trading on Friday, reaching $42.98. 324,236 shares of the company's stock traded hands, compared to its average volume of 701,612. The company has a 50-day moving average price of $47.73 and a two-hundred day moving average price of $49.14. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The firm has a market capitalization of $1.81 billion, a PE ratio of -11.28 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. As a group, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $50.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now owns 824,106 shares of the company's stock, valued at $41,205,300. This represents a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the transaction, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. This represents a 5.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,542 shares of company stock valued at $1,581,173 in the last 90 days. 8.25% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.